Neurosurgeon John Sampson joins Labcorp (NYSE: LH) board

Rhea-AI Filing Summary

Labcorp Holdings Inc. has appointed John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026, and named him to the Board’s Quality and Compliance Committee.

Dr. Sampson is vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine and previously held senior leadership roles at Duke University Health System. He is a nationally recognized neurosurgeon and physician-scientist with nearly 300 peer-reviewed publications and extensive experience in oncology, neuroscience, women’s health and personalized medicine. He will receive board compensation consistent with Labcorp’s existing director compensation program.

8-K Event Classification

3 items: 5.02, 7.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0000920148false00009201482026-02-062026-02-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

February 6, 2026

(Date of earliest event reported)

LABCORP HOLDINGS INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

1-11353

99-2588107

(State or other jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

358 South Main Street

Burlington

,

North Carolina

27215

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number including area code) 336-229-1127

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class

Trading Symbol

Name of exchange on which registered

Common Stock, $0.10 par value

LH

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).             

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 5.02			Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Labcorp Holdings Inc. (the “Company”) today announced that on February 6, 2026, the Company’s Board of Directors (the “Board”) appointed John H. Sampson, M.D., Ph.D., as a member of the Board, effective February 9, 2026. In connection with Dr. Sampson’s appointment, the Board has appointed Dr. Sampson to the Quality and Compliance Committee. Dr. Sampson will be entitled to receive compensation for his service on the Board consistent with the Company’s director compensation program, as described in the Company's most recent proxy statement, filed with the Securities and Exchange Commission on April 4, 2025. Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. Before joining the CU Anschutz School of Medicine, Dr. Sampson held senior leadership roles at Duke University Health System, where he served as senior vice president and led the Duke Health Integrated Practice. He is a practicing neurosurgeon, a member of the National Academy of Medicine, and has authored nearly 300 peer-reviewed publications, with a long track record of research focused on advancing new therapies for neurologic disease.
Item 7.01			Regulation FD Disclosure.
On February 9, 2026, the Company issued a press release announcing the appointment of Dr. Sampson to the Board. A copy of that press release is attached to, and incorporated by reference into, this current report as Exhibit 99.1.

Item 9.01			Financial Statements and Exhibits.
Exhibit			Exhibit Name
Exhibit 99.1			Press Release dated February 9, 2026 issued by the Company
Exhibit 104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABCORP HOLDINGS INC.

Registrant

Date: February 9, 2026			By:			/s/ KATHRYN W. KYLE
						Kathryn W. Kyle
						Executive Vice President, Chief Legal Officer and Corporate Secretary

FOR IMMEDIATE RELEASE

Neil Hirsch - Media						Christin O’Donnell - Investors
Media@Labcorp.com						Investor@Labcorp.com

Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors

BURLINGTON, N.C., (February 9, 2026) — Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026.

Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical research, medical education and large-scale health system leadership. He also has deep expertise in oncology, neuroscience, women’s health and personalized medicine which aligns with Labcorp’s strategic areas of focus.

“John is widely respected as a leader in academic medicine, clinical practice, health system strategy and research,” said Adam Schechter, Chairman and Chief Executive Officer of Labcorp. “His expertise will help advance Labcorp’s strategy across diagnostics and drug development and enhance the value we deliver to customers.”

Before joining the CU Anschutz School of Medicine, Dr. Sampson held senior leadership roles at Duke University Health System, where he served as senior vice president and led the Duke Health Integrated Practice. He is a practicing neurosurgeon, a member of the National Academy of Medicine, and has authored nearly 300 peer-reviewed publications, with a long track record of research focused on advancing new therapies for neurologic disease.

“Labcorp plays a critical role in advancing earlier diagnosis, personalized medicine and the development of new therapies,” said Dr. Sampson. “I look forward to contributing my clinical and research experience to help further the company’s mission of improving health and improving lives.”

In connection with Dr. Sampson’s appointment, the Board has appointed Dr. Sampson to the Quality and Compliance Committee.

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.

1

FAQ

What board change did Labcorp (LH) announce on February 9, 2026?

Labcorp announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026. He also joined the Board’s Quality and Compliance Committee as part of this governance update.

Who is John H. Sampson, the new Labcorp (LH) board member?

John H. Sampson is a neurosurgeon, physician-scientist and academic leader serving as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine. He has held senior leadership roles at Duke University Health System and authored nearly 300 peer-reviewed publications.

What committee will John H. Sampson serve on at Labcorp (LH)?

In addition to joining Labcorp’s Board of Directors, John H. Sampson has been appointed to the company’s Quality and Compliance Committee. This role aligns with his background in clinical care, biomedical research, medical education and large-scale health system leadership.

What experience does John H. Sampson bring to Labcorp’s (LH) board?

Dr. Sampson brings extensive experience in clinical care, biomedical research, medical education and large health system leadership. He has deep expertise in oncology, neuroscience, women’s health and personalized medicine, areas that align with Labcorp’s strategic focus across diagnostics and drug development.

How will John H. Sampson be compensated for his Labcorp (LH) board role?

John H. Sampson will receive compensation consistent with Labcorp’s existing director compensation program. The structure of this program is described in Labcorp’s most recent proxy statement filed with the Securities and Exchange Commission on April 4, 2025.

Did Labcorp (LH) issue a press release about John H. Sampson’s appointment?

Labcorp issued a press release on February 9, 2026 announcing John H. Sampson’s appointment to the Board of Directors. That press release is included as Exhibit 99.1 and incorporated by reference in the company’s current report.

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 7.5 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2.0 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.3 KB